Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

U0289-404: An Evaluator Blinded, 8 Week, Split Face Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITYII and MURAD in Subjects With Acne

NCT02524665 is registered in ClinicalTrials.gov with Stiefel, a GSK Company as lead sponsor.

NCT NCT02524665
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02524665 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
U0289-404: An Evaluator Blinded, 8 Week, Split Face Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITYII and MURAD in Subjects With Acne
Lead sponsor
Stiefel, a GSK Company
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2009
Completion date
December 31, 2009
Enrollment
20 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acne vulgaris